Synvista Therapeutics (SYI) Announces FDA Received Its Application for 510(k) Clearance for HAPTOCHEK(TM) Test Kit
Synvista Therapeutics, Inc. (AMEX: SYI) today announced that it has submitted, and that the FDA has received its application for 510(k) clearance for its HAPTOCHEK(TM) diagnostic test kit. The 510(k) submission begins a 90-day review process, during which the FDA will determine whether the kit can be distributed to labs throughout the country as an in vitro diagnostic.
Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease.
Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- AVEO Oncology (AVEO) Commences AV-203 Phase 1 in Advanced Solid Tumors
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
